AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours

Inclusion Criteria: * Histologically or cytologically confirmed metastatic cancer, not amenable to surgery or radiation therapy with curative intent * Measurable or evaluable disease * ECOG Performance status 0 - 2 * Estimated life expectancy of at least 12 weeks Exclusion Criteria: * More than 3 prior lines of chemotherapy for advanced disease * Less than 28 days from active treatment (ie, any treatment used to treat the disease) or high dose radiotherapy (patients may continue concomitant use of stable dose of bisphosphonates if used at least 28 days prior to commencing study treatment and pat * Prior treatment with \>300mg/m2 cumulative dose of doxorubicin equivalent * Resistance to anthracyclines defined as progressive disease during anthracycline treatment or within 6 months after the last anthracycline administration.